Skip to main content

Advertisement

SpringerLink
Log in

Pharmacologic Stress Using Selective A2A Adenosine Receptor Agonists

  • Published:
Current Cardiovascular Imaging Reports Aims and scope Submit manuscript

Abstract

Adenosine and dipyridamole are nonselective A2A adenosine receptor agonists that provide reproducible coronary vasodilation thereby inducing flow disparities in the setting of physiologically important coronary stenosis. Although myocardial perfusion imaging in conjunction with pharmacologic stress with both agents has yielded high diagnostic accuracy and overall safety, limitations include concerns in selected populations, such as those with bronchospastic lung disease and heart block, frequent side effects, and a complicated method of delivery (sustained intravenous infusion). Regadenoson, binodenoson, and apadenoson are selective A2A adenosine receptor agonists that have been shown to provide more selective coronary vasodilatation, with improved safety profiles and patient tolerability. Additionally, these new agents may be delivered by an intravenous bolus eliminating the requirement for an infusion pump. Regadenoson is already in widespread clinical use in the United States. Binodenoson completed phase 3 clinical trials but has not yet been approved for clinical use. Apadenoson is currently in pivotal phase 3 clinical trials.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Klocke FJ, Baird MG, Lorell BH, Bateman TM, Messer JV, Berman DS, et al. ACC/AHA/ASNC guidelines for the clinical use of cardiac radionuclide imaging—executive summary: a report of the American college of cardiology/American heart association task force on practice guidelines (ACC/AHA/ASNC committee to revise the 1995 guidelines for the clinical use of cardiac radionuclide imaging). J Am Coll Cardiol. 2003;42:1318–33.

    Article  PubMed  Google Scholar 

  2. Anagnostopoulos C, Harbinson M, Kelion A, Kundley K, Loong CY, Notghi A, et al. Procedure guidelines for radionuclide myocardial perfusion imaging. Heart. 2004;90 Suppl 1:i1–10.

    Article  PubMed  Google Scholar 

  3. Hendel RC, Jamil T, Glover DK. Pharmacologic stress testing: new methods and new agents. J Nucl Cardiol. 2003;10:197–204.

    Article  PubMed  Google Scholar 

  4. Verani MS, Mahmarian JJ. Pharmacological stress nuclear cardiology imaging. Am J Card Imaging. 1994;8:223–30.

    PubMed  CAS  Google Scholar 

  5. Brindis RG, Douglas PS, Hendel RC, Peterson ED, Wolk MJ, Allen JM, et al. ACCF/ASNC appropriateness criteria for single-photon emission computed tomography myocardial perfusion imaging (SPECT MPI): a report of the American college of cardiology foundation quality strategic directions committee appropriateness criteria working group and the American society of nuclear cardiology endorsed by the American heart association. J Am Coll Cardiol. 2005;46:1587–605.

    Article  PubMed  Google Scholar 

  6. Cerqueira MD. Advances in pharmacologic agents in imaging: new A2A receptor agonists. Curr Cardiol Rep. 2006;8:119–22.

    Article  PubMed  Google Scholar 

  7. Bertolet BD, Hill JA. Adenosine: diagnostic and therapeutic uses in cardiovascular medicine. Chest. 1993;104:1860–71.

    Article  PubMed  CAS  Google Scholar 

  8. Biaggioni I, Olafsson B, Robertson RM, Hollister AS, Robertson D. Cardiovascular and respiratory effects of adenosine in conscious man. Evidence for chemoreceptor activation. Circ Res. 1987;61:779–86.

    PubMed  CAS  Google Scholar 

  9. Spicuzza L, Di Maria G, Polosa R. Adenosine in the airways: implications and applications. Eur J Pharmacol. 2006;533:77–88.

    Article  PubMed  CAS  Google Scholar 

  10. Cerqueira MD. The future of pharmacologic stress: selective A2A adenosine receptor agonists. Am J Cardiol. 2004;94:33D–40. discussion 40D-42D.

    Article  PubMed  CAS  Google Scholar 

  11. Travin MI, Wexler JP. Pharmacological stress testing. Semin Nucl Med. 1999;29:298–318.

    Article  Google Scholar 

  12. Belardinelli L, Shryock JC, Snowdy S, Zhang Y, Monopoli A, Lozza G, et al. The A2A adenosine receptor mediates coronary vasodilation. J Pharmacol Exp Ther. 1998;284:1066–73.

    PubMed  CAS  Google Scholar 

  13. Martin PM, Ueeda M, Olsson RA. 2-Phenylethoxy-9-methyladenine: an adenosine receptor antagonist that discriminates between A2 adenosine receptors in the aorta and coronary vessels from the guinea pig. J Pharmacol Exp Ther. 1993;265:248–53.

    PubMed  CAS  Google Scholar 

  14. Hein TW, Belardinelli L, Kuo L. Adenosine A(2A) receptors mediate coronary microvascular dilation to adenosine: role of nitric oxide and ATP-sensitive potassium channels. J Pharmacol Exp Ther. 1999;291:655–64.

    PubMed  CAS  Google Scholar 

  15. Hein TW, Kuo L. cAMP-independent dilation of coronary arterioles to adenosine: role of nitric oxide, G proteins, and K(ATP) channels. Circ Res. 1999;85:634–42.

    PubMed  CAS  Google Scholar 

  16. Abreu A, Mahmarian JJ, Nishimura S, Boyce TM, Verani MS. Tolerance and safety of pharmacologic coronary vasodilation with adenosine in association with thallium-201 scintigraphy in patients with suspected coronary artery disease. J Am Coll Cardiol. 1991;18:730–5.

    Article  PubMed  CAS  Google Scholar 

  17. Cerqueira MD, Verani MS, Schwaiger M, Heo J, Iskandrian AS. Safety profile of adenosine stress perfusion imaging: results from the adenoscan multicenter trial registry. J Am Coll Cardiol. 1994;23:384–9.

    Article  PubMed  CAS  Google Scholar 

  18. Gupta NC, Esterbrooks DJ, Hilleman DE, Mohiuddin SM. Comparison of adenosine and exercise thallium-201 single-photon emission computed tomography (SPECT) myocardial perfusion imaging. The GE SPECT multicenter adenosine study group. J Am Coll Cardiol. 1992;19:248–57.

    Article  PubMed  CAS  Google Scholar 

  19. Johnston DL, Daley JR, Hodge DO, Hopfenspirger MR, Gibbons RJ. Hemodynamic responses and adverse effects associated with adenosine and dipyridamole pharmacologic stress testing: a comparison in 2,000 patients. Mayo Clin Proc. 1995;70:331–6.

    Article  PubMed  CAS  Google Scholar 

  20. Lette J, Tatum JL, Fraser S, Miller DD, Waters DD, Heller G, et al. Safety of dipyridamole testing in 73,806 patients: the multicenter dipyridamole safety study. J Nucl Cardiol. 1995;2:3–17.

    Article  PubMed  CAS  Google Scholar 

  21. •• Cerqueira MD, Nguyen P, Staehr P, Underwood SR, Iskandrian AE. Effects of age, gender, obesity, and diabetes on the efficacy and safety of the selective A2A agonist regadenoson versus adenosine in myocardial perfusion imaging integrated ADVANCE-MPI trial results. J Am Coll Cardiol Cardiovasc Imag. 2008;1:307–16. These are the results of the combined pivotal phase 3 studies comparing the efficacy and safety of regadenoson versus adenosine. In addition to the pooled analysis showing non-inferiority of regadenoson to adenosine for detecting the presence and extent of CAD, the authors demonstrated that the agreement was consistent across various subpopulations that were examined.

    Google Scholar 

  22. Dhalla AK, Wong MY, Wang WQ, Biaggioni I, Belardinelli L. Tachycardia caused by A2A adenosine receptor agonists is mediated by direct sympathoexcitation in awake rats. J Pharmacol Exp Ther. 2006;316:695–702.

    Article  PubMed  CAS  Google Scholar 

  23. Lieu HD, Shryock JC, von Mering GO, Gordi T, Blackburn B, Olmsted AW, et al. Regadenoson, a selective A2A adenosine receptor agonist, causes dose-dependent increases in coronary blood flow velocity in humans. J Nucl Cardiol. 2007;14:514–20.

    Article  PubMed  Google Scholar 

  24. Gordi T, Blackburn B, Lieu H. Regadenoson pharmacokinetics and tolerability in subjects with impaired renal function. J Clin Pharmacol. 2007;47:825–33.

    Article  PubMed  CAS  Google Scholar 

  25. •• Iskandrian AE, Bateman TM, Belardinelli L, Blackburn B, Cerqueira MD, Hendel RC, Lieu H, Mahmarian JJ, Olmsted A, Underwood SR, Vitola J, Wang W. Adenosine versus regadenoson comparative evaluation in myocardial perfusion imaging: results of the ADVANCE phase 3 multicenter international trial. J Nucl Cardiol. 2007;14:645–58. This paper presents the results of the pivotal phase 3 multicenter clinical trials comparing the efficacy and safety of regadenoson versus adenosine.

    Article  PubMed  Google Scholar 

  26. Leaker BR, O'Connor B, Hansel TT, Barnes PJ, Meng L, Mathur VS, et al. Safety of regadenoson, an adenosine A2A receptor agonist for myocardial perfusion imaging, in mild asthma and moderate asthma patients: a randomized, double-blind, placebo-controlled trial. J Nucl Cardiol. 2008;15:329–36.

    Article  PubMed  Google Scholar 

  27. Thomas GS, Tammelin BR, Schiffman GL, Marquez R, Rice DL, Milikien D, et al. Safety of regadenoson, a selective adenosine A2A agonist, in patients with chronic obstructive pulmonary disease: a randomized, double-blind, placebo-controlled trial (RegCOPD trial). J Nucl Cardiol. 2008;15:319–28.

    Article  PubMed  Google Scholar 

  28. Astellas Pharma US Inc. Lexiscan™ (regadenoson) injection. United States prescribing information. April 2008. Available at http://www.astellas.us/docs/lexiscan.xml

  29. Hodgson JM, Dib N, Kern MJ, Bach RG, Barrett RJ. Coronary circulation responses to binodenoson, a selective adenosine A2A receptor agonist. Am J Cardiol. 2007;99:1507–12.

    Article  PubMed  CAS  Google Scholar 

  30. • Udelson JE, Heller GV, Wackers FJ, Chai A, Hinchman D, Coleman PS, Dilsizian V, DiCarli M, Hachamovitch R, Johnson JR, Barrett RJ, Gibbons RJ. Randomized, controlled dose-ranging study of the selective adenosine A2A receptor agonist binodenoson for pharmacological stress as an adjunct to myocardial perfusion imaging. Circulation. 2004;109:457–64. This paper presents the phase 2 clinical trial data comparing the efficacy and safety of binodenoson with adenosine. The results of this study established the optimal dose to go forward for phase 3.

    Article  PubMed  CAS  Google Scholar 

  31. Udelson JE, Iteld B, Weiland F, Foster J, Bonow R, Ficaro E, Gibbons RJ, Heller G, Wackers FJ, Barrett RJ, Pixton GC. Vasodilator induced stress in concordance with adenosine. Vision: binodenoson pivotal clinical trial program. March, 2008. [online] Available at: http://www.clinicaltrialresults.org/Slides/VISION%20Phase3%20for%20clinical%20trials.org%20%20Udelson.ppt

  32. Kern MJ, Hodgson JM, Dib N, Mittleman RS, Crane PD. Effects of apadenoson, a selective adenosine A2A receptor agonist for myocardial perfusion imaging, on coronary blood flow velocity in conscious patients. Circulation. 2006;114:II_582a.

    Article  Google Scholar 

  33. Glover DK, Ruiz M, Takehana K, Petruzella FD, Riou LM, Rieger JM, et al. Pharmacological stress myocardial perfusion imaging with the potent and selective A(2A) adenosine receptor agonists ATL193 and ATL146e administered by either intravenous infusion or bolus injection. Circulation. 2001;104:1181–7.

    Article  PubMed  CAS  Google Scholar 

  34. • Hendel R, Taillefer R, Crane P, Widner P. Preliminary experience with BMS068645, a selective A2A adenosine agonist, for pharmacologic stress myocardial perfusion imaging. Circulation. 2005;112:474. Early results using apadenoson in patients for pharmacologic stress imaging. The results show excellent agreement between apadenoson and adenosine for the detection of the presence and extent of CAD, and an excellent safety profile.

    Google Scholar 

  35. Thomas GS, Thompson RC, Miyamoto MI, Ip TK, Rice DL, Milikien D, et al. The RegEx trial: a randomized, double-blind, placebo- and active-controlled pilot study combining regadenoson, a selective A(2A) adenosine agonist, with low-level exercise, in patients undergoing myocardial perfusion imaging. J Nucl Cardiol. 2009;16:63–72.

    Article  PubMed  Google Scholar 

  36. Kwon DH, Cerqueira MD, Young R, Houghtaling P, Lieber E, Menon V, et al. Lessons from regadenoson and low-level treadmill/regadenoson myocardial perfusion imaging: initial clinical experience in 1263 patients. J Nucl Cardiol. 2010;17:853–7.

    Article  PubMed  Google Scholar 

  37. Elliott MD, Holly TA, Leonard SM, Hendel RC. Impact of an abbreviated adenosine protocol incorporating adjunctive treadmill exercise on adverse effects and image quality in patients undergoing stress myocardial perfusion imaging. J Nucl Cardiol. 2000;7:584–9.

    Article  PubMed  CAS  Google Scholar 

  38. Murray JJ, Weiler JM, Schwartz LB, Busse WW, Katial RK, Lockey RF, et al. Safety of binodenoson, a selective adenosine A2A receptor agonist vasodilator pharmacological stress agent, in healthy subjects with mild intermittent asthma. Circ Cardiovasc Imag. 2009;2:492–8.

    Article  Google Scholar 

  39. Williams S, Colice G, McArdle J, Lankford A, Zou W, Reed C. A randomized, double-blind placebo-controlled study of the safety of apadenoson in subjects with moderate-to-severe chronic obstructive pulmonary disease. J Nucl Cardiol. 2010;17:725.

    Article  Google Scholar 

  40. Williams S, McArdle J, Colice G, Lankford A, Zou W, Reed C. A randomized double-blind placebo-controlled study of the safety of apadenoson in subjects with mild or moderate asthma. J Nucl Cardiol. 2010;17:724.

    Article  Google Scholar 

  41. Laighold S, Druz R. Initial clinical experience with a selective A2A receptor agonist, regadenoson, in a patient with end-stage renal disease on hemodialysis. J Nucl Cardiol. 2009;16:478–80.

    Article  PubMed  Google Scholar 

  42. Aljaroudi W, Hermann D, Hage F, Heo J, Iskandrian AE. Safety of regadenoson in patients with end-stage renal disease. Am J Cardiol. 2010;105:133–5.

    Article  PubMed  CAS  Google Scholar 

  43. Aljaroudi W, Iqbal F, Koneru J, Bhambhvani P, Heo J, Iskandrian AE. Safety of regadenoson in patients with end-stage liver disease. J Nucl Cardiol. 2011;18:90–5.

    Article  PubMed  Google Scholar 

  44. Lapeyre 3rd AC, Goraya TY, Johnston DL, Gibbons RJ. The impact of caffeine on vasodilator stress perfusion studies. J Nucl Cardiol. 2004;11:506–11.

    Article  PubMed  Google Scholar 

  45. Smits P, Schouten J, Thien T. Cardiovascular effects of two xanthines and the relation to adenosine antagonism. Clin Pharmacol Ther. 1989;45:593–9.

    Article  PubMed  CAS  Google Scholar 

  46. Zoghbi GJ, Htay T, Aqel R, Blackmon L, Heo J, Iskandrian AE. Effect of caffeine on ischemia detection by adenosine single-photon emission computed tomography perfusion imaging. J Am Coll Cardiol. 2006;47:2296–302.

    Article  PubMed  CAS  Google Scholar 

  47. Heller GV, Dweik RB, Barbour MM, Garber CE, Cloutier DJ, Messinger DE, et al. Pretreatment with theophylline does not affect adenosine-induced thallium-201 myocardial imaging. Am Heart J. 1993;126:1077–83.

    Article  PubMed  CAS  Google Scholar 

  48. Zhao G, Messina E, Xu X, Ochoa M, Sun HL, Leung K, et al. Caffeine attenuates the duration of coronary vasodilation and changes in hemodynamics induced by regadenoson (CVT-3146), a novel adenosine A2A receptor agonist. J Cardiovasc Pharmacol. 2007;49:369–75.

    Article  PubMed  CAS  Google Scholar 

  49. Gaemperli O, Schepis T, Koepfli P, Siegrist PT, Fleischman S, Nguyen P, et al. Interaction of caffeine with regadenoson-induced hyperemic myocardial blood flow as measured by positron emission tomography: a randomized, double-blind, placebo-controlled crossover trial. J Am Coll Cardiol. 2008;51:328–9.

    Article  PubMed  Google Scholar 

  50. Tejani FH, Thompson RC, Iskandrian AE, McNutt BE, Franks B. Effect of caffeine on SPECT myocardial perfusion imaging during regadenoson pharmacologic stress: rationale and design of a prospective, randomized, multicenter study. J Nucl Cardiol. 2011;18:73–81.

    Article  PubMed  Google Scholar 

  51. Gemignani AS, Abbott BG. The emerging role of the selective A2A agonist in pharmacologic stress testing. J Nucl Cardiol. 2010;17:494–7.

    Article  PubMed  Google Scholar 

Download references

Disclosure

R. C. Hendel: consultant to Trovis Pharmaceuticals; N. A. Moreno: none; D. K. Glover: consultant to Trovis Pharmaceuticals and royalties from Adenosine Therapeutics, LLC.

Author information

Authors and Affiliations

  1. University of Virginia Health System, PO Box 801394, Charlottesville, VA, 22908–1394, USA

    David K. Glover

  2. University of Miami Miller School of Medicine, 1120 NW 14th Street Suite 1123, CRB Miami, FL, 33136, USA

    Robert C. Hendel & Niberto A. Moreno

Authors
  1. Robert C. Hendel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Niberto A. Moreno
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. David K. Glover
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to David K. Glover.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hendel, R.C., Moreno, N.A. & Glover, D.K. Pharmacologic Stress Using Selective A2A Adenosine Receptor Agonists. Curr Cardiovasc Imaging Rep 4, 217–226 (2011). https://doi.org/10.1007/s12410-011-9086-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12410-011-9086-4

Keywords

Search

Navigation